Literature DB >> 24705570

Low respiratory rate plus minimally invasive extracorporeal Co2 removal decreases systemic and pulmonary inflammatory mediators in experimental Acute Respiratory Distress Syndrome.

Salvatore Grasso1, Tania Stripoli, Palma Mazzone, Marco Pezzuto, Luca Lacitignola, Paola Centonze, Alessandro Guarracino, Cosimo Esposito, Peter Herrmann, Michael Quintel, Paolo Trerotoli, Francesco Bruno, Antonio Crovace, Francesco Staffieri.   

Abstract

OBJECTIVE: The Acute Respiratory Distress Syndrome Network protocol recommends limiting tidal volume and plateau pressure; it also recommends increasing respiratory rate to prevent hypercapnia. We tested a strategy that combines the low tidal volume with lower respiratory rates and minimally invasive CO2 removal.
SUBJECTS: Ten lung-damaged pigs (instilled hydrochloride).
INTERVENTIONS: Two conditions randomly applied in a crossover fashion: the Acute Respiratory Distress Syndrome Network protocol and the Acute Respiratory Distress Syndrome Network protocol plus lower respiratory rate plus minimally invasive Co2 removal. A similar arterial Co2 partial pressure was targeted in the two conditions.
MEASUREMENTS AND MAIN RESULTS: Physiological parameters, computed tomography scans, plasma and bronchoalveolar lavage concentrations of interleukin-1β, interleukin-6, interleukin-8, interleukin-10, interleukin-18, and tumor necrosis factor-α. During the lower respiratory rate condition, respiratory rate was reduced from 30.5 ± 3.8 to 14.2 ± 3.5 (p < 0.01) breaths/min and minute ventilation from 10.4 ± 1.6 to 4.9 ± 1.7 L/min (p < 0.01). The extracorporeal device removed 38.9% ± 6.1% (79.9 ± 18.4 mL/min) of CO2 production. During the lower respiratory rate condition, interleukin-6, interleukin-8, and tumor necrosis factor-α concentrations were significantly lower in plasma; interleukin-6 and tumor necrosis factor-α concentrations were lower in bronchoalveolar lavage, whereas the concentrations of the other cytokines remained unchanged.
CONCLUSION: The strategy of lower respiratory rate plus minimally invasive extracorporeal CO2 removal was feasible and safe and, as compared with the Acute Respiratory Distress Syndrome Network protocol, reduced the concentrations of some, but not all, of the tested cytokines without affecting respiratory mechanics, gas exchange, and hemodynamics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24705570     DOI: 10.1097/CCM.0000000000000312

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  10 in total

Review 1.  Extracorporeal techniques in acute respiratory distress syndrome.

Authors:  Madhavi Parekh; Darryl Abrams; Daniel Brodie
Journal:  Ann Transl Med       Date:  2017-07

Review 2.  Extracorporeal carbon dioxide removal (ECCO2R) in patients with acute respiratory failure.

Authors:  Andrea Morelli; Lorenzo Del Sorbo; Antonio Pesenti; V Marco Ranieri; Eddy Fan
Journal:  Intensive Care Med       Date:  2017-01-28       Impact factor: 17.440

3.  Feasibility and safety of extracorporeal CO2 removal to enhance protective ventilation in acute respiratory distress syndrome: the SUPERNOVA study.

Authors:  Alain Combes; Vito Fanelli; Tai Pham; V Marco Ranieri
Journal:  Intensive Care Med       Date:  2019-02-21       Impact factor: 17.440

4.  Potentially modifiable factors contributing to outcome from acute respiratory distress syndrome: the LUNG SAFE study.

Authors:  John G Laffey; Giacomo Bellani; Tài Pham; Eddy Fan; Fabiana Madotto; Ednan K Bajwa; Laurent Brochard; Kevin Clarkson; Andres Esteban; Luciano Gattinoni; Frank van Haren; Leo M Heunks; Kiyoyasu Kurahashi; Jon Henrik Laake; Anders Larsson; Daniel F McAuley; Lia McNamee; Nicolas Nin; Haibo Qiu; Marco Ranieri; Gordon D Rubenfeld; B Taylor Thompson; Hermann Wrigge; Arthur S Slutsky; Antonio Pesenti
Journal:  Intensive Care Med       Date:  2016-10-18       Impact factor: 17.440

5.  Safety and Efficacy of Combined Extracorporeal CO2 Removal and Renal Replacement Therapy in Patients With Acute Respiratory Distress Syndrome and Acute Kidney Injury: The Pulmonary and Renal Support in Acute Respiratory Distress Syndrome Study.

Authors:  Jérôme Allardet-Servent; Matthias Castanier; Thomas Signouret; Rettinavelou Soundaravelou; Anne Lepidi; Jean-Marie Seghboyan
Journal:  Crit Care Med       Date:  2015-12       Impact factor: 7.598

6.  A 2-year multicenter, observational, prospective, cohort study on extracorporeal CO2 removal in a large metropolis area.

Authors:  J L Augy; N Aissaoui; C Richard; E Maury; M Fartoukh; A Mekontso-Dessap; R Paulet; N Anguel; C Blayau; Y Cohen; J D Chiche; S Gaudry; S Voicu; A Demoule; A Combes; B Megarbane; E Charpentier; S Haghighat; M Panczer; J L Diehl
Journal:  J Intensive Care       Date:  2019-08-20

7.  Extracorporeal carbon dioxide removal requirements for ultraprotective mechanical ventilation: Mathematical model predictions.

Authors:  John Kenneth Leypoldt; Jacques Goldstein; Dominique Pouchoulin; Kai Harenski
Journal:  Artif Organs       Date:  2019-12-15       Impact factor: 3.094

8.  Positive End-Expiratory Pressure and Respiratory Rate Modify the Association of Mechanical Power and Driving Pressure With Mortality Among Patients With Acute Respiratory Distress Syndrome.

Authors:  Joseph E Tonna; Ithan D Peltan; Samuel M Brown; Colin K Grissom; Angela P Presson; Jennifer S Herrick; Francesco Vasques; Heather T Keenan
Journal:  Crit Care Explor       Date:  2021-12-09

Review 9.  Extracorporeal life support for adults with acute respiratory distress syndrome.

Authors:  Alain Combes; Matthieu Schmidt; Carol L Hodgson; Eddy Fan; Niall D Ferguson; John F Fraser; Samir Jaber; Antonio Pesenti; Marco Ranieri; Kathryn Rowan; Kiran Shekar; Arthur S Slutsky; Daniel Brodie
Journal:  Intensive Care Med       Date:  2020-11-02       Impact factor: 17.440

10.  On the Transition from Control Modes to Spontaneous Modes during ECMO.

Authors:  Krista Stephens; Nathan Mitchell; Sean Overton; Joseph E Tonna
Journal:  J Clin Med       Date:  2021-03-02       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.